Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Slides:

Advertisements

Similar presentations

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Advertisements

Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Around-the-Clock, Controlled-Release Oxycodone Therapy.

Copyright © 2003 American Medical Association. All rights reserved.

Daniel J. Lenihan et al. BTS 2016;1:

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Volume 88, Issue 6, Pages (December 2015)

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

Volume 88, Issue 2, Pages (August 2015)

Volume 65, Issue 5, Pages (May 2004)

Differing renal outcomes associated with AKI electronic alerts for clinical location of AKI subsets. Differing renal outcomes associated with AKI electronic.

M.R. Jacobs Clinical Microbiology and Infection

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

American Journal of Kidney Diseases

Study design (A) and subject disposition (B).

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Trend of overall improvement in CKD risk categories after bariatric surgery using year 1 post-surgery as baseline. Trend of overall improvement in CKD.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

UK improves survival. UK improves survival. Following SNx, rats were divided into SNx untreated (disease, n=24; half those remaining were.

Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels in dialysis patients. Vitamin K2 supplementation reduces dp-ucMGP but not dp-cMGP levels.

Within-group comparisons of adjusted mean±SEM of absolute change in peak systolic strain (%) from baseline to 12 months using the American Heart Association.

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

Maximum mean (SE) per cent change in serum urate from baseline (Emax) following once-daily oral administration of varying verinurad doses in combination.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

In-hospital outcomes: community- versus hospital-acquired AKI

Lifestyle intervention was associated with improved cardiorespiratory fitness. Lifestyle intervention was associated with improved cardiorespiratory fitness.

Intrapatient variability in cyclosporine blood levels in renal transplant patients. Intrapatient variability in cyclosporine blood levels in renal transplant.

Proteinuria trend versus time for seven patients who achieved remission with adrenocorticotropic hormone (ACTH). Proteinuria trend versus time for seven.

More women are affected than men in X-linked Alport syndrome.

Ratio of actual to expected rise in sodium as calculated using the Adrogué-Madias formula. Ratio of actual to expected rise in sodium as calculated using.

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

Renal units with renal scarring by vesicoureteral reflux (VUR) grade.

Ca2+ infusion rates during all three protocol versions.

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

PTH response to the predialysis serum calcium concentration in hemodialysis patients with severe (A), moderate (B), and mild (C) hyperparathyroidism. PTH.

A loading dose decreases the time to achieve the target concentration.

Clinical characteristics and laboratory parameters in relation to dose of oral sodium bicarbonate. Clinical characteristics and laboratory parameters in.

Response to cyclosporin A (CsA) treatment and renal outcome in patients with either nongenetic or genetic disease. Response to cyclosporin A (CsA) treatment.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Mortality predictability of the difference of the percentiles of the changes in dietary protein intake, represented by nPNA (nPCR), and serum P concentration.

Cytokine changes in LPS-induced TNFα and spontaneous IL-6 production in whole-blood cultures. Cytokine changes in LPS-induced TNFα and spontaneous IL-6.

Graph showing percentage of total patients with PTD or IGT that would be detected in each category of FBG if an oral glucose tolerance test were performed.

Six-month change in proteinuria predicts risk for ESRD

The same daily dose of metformin administered as different dosage regimens has differing effects on the concentration–time profile in a patient with CKD.

Mortality caused by cardiovascular disease (A) and sepsis (B) of patients with end-stage renal disease (ESRD) treated by dialysis compared with the general.

(A) Erythropoietin response for all subjects, plotted by numerator and denominator of the measure. (A) Erythropoietin response for all subjects, plotted.

mTORC1 is required for malignant transformation in the Eμ-Myc model.

We identified 200 Android and 178 iOS apps using 4 search terms and narrowed this to 12 Android apps, 11 iOS apps, and 5 dual-platform apps after applying.

Distribution of percent consistent facility aspirin use.

Changes in 44-hour interdialytic systolic BP as a function of change in echocardiographic volume parameter. Changes in 44-hour interdialytic systolic BP.

New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.

Aliskiren, the orally effective renin inhibitor, provides antihypertensive efficacy at least equivalent to the ARB irbesartan in patients with hypertension.

Distribution of SDS for serum creatinine, serum BUN, SBP, and DBP per quintiles of KS. Quintiles are expressed in SDS (see Figure 1B): 1st quintile,

As the patient nears the end of life (dashed arrow), there is an increasing focus on symptom control and patient goals of care and a shift in the approach.

Misclassification of obesity using BMI compared with DEXA and association with sarcopenia. Misclassification of obesity using BMI compared with DEXA and.

Change in coronary artery calcification in patients who were treated with calcium or sevelamer. Change in coronary artery calcification in patients who.

Pancreas transplantation is performed at transplant centers within 56 of the 58 federally designated donor service areas (DSAs). Pancreas transplantation.

Study design. aPatients initially receiving tenapanor 30 mg twice a day were allowed to down-titrate weekly (stepwise 30 → 20 → 15 → 10 → 3 mg twice a.

Study protocol. Study protocol. All participants were studied on four occasions: Twice before and twice after an 8-wk treatment period on low-dosage, low.

Mean number of dialysis sessions per patient for which intradialytic hypotension–related nursing interventions were required during the first 2 wk and.

Peritonitis treatment algorithm.

Effect of aspirin (ASA) on serum cytokine concentration in hemodialysis (HD) patients. Effect of aspirin (ASA) on serum cytokine concentration in hemodialysis.

Data normalization process.

Distribution of facility mean treatment time, by DOPPS region and phase. Distribution of facility mean treatment time, by DOPPS region and phase. Restricted.

Presentation transcript:

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%, 3% and 0% of placebo-treated patients, respectively. Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%, 3% and 0% of placebo-treated patients, respectively. Category of change from baseline in serum bicarbonate at day 15. Percentages of patients (y axis), including the percentages of patients (above bars) in the respective treatment groups, achieving defined increases of serum bicarbonate from baseline (x axis) corresponding to <2, ≥2, ≥3, ≥4, ≥5, ≥6, and ≥7 mEq/L are shown. The percentage of patients in the respective treatment groups achieving a defined increase of serum bicarbonate from baseline was calculated on the basis of the number of patients who reached the given value divided by the total number of patients in the treatment group (summarized in Figures 1 and 2). The numbers of patients in each treatment group attaining the given change from baseline in serum bicarbonate were <2 mEq/L (pooled placebo =27, TRC101 1.5 g twice daily =7, TRC101 6 g once daily =5, TRC101 3 g twice daily =11, TRC101 4.5 g twice daily =7), ≥2 mEq/L (pooled placebo =4, TRC101 1.5 g twice daily =18, TRC101 6 g once daily =23, TRC101 3 g twice daily =14, TRC101 4.5 g twice daily =19), ≥3 mEq/L (pooled placebo =2, TRC101 1.5 g twice daily =14, TRC101 6 g once daily =14, TRC101 3 g twice daily =10, TRC101 4.5 g twice daily =16), ≥4 mEq/L (pooled placebo =1, TRC101 1.5 g twice daily =8, TRC101 6 g once daily =12, TRC101 3 g twice daily =10, TRC101 4.5 g twice daily =11), ≥5 mEq/L (pooled placebo =0, TRC101 1.5 g twice daily =3, TRC101 6 g once daily =6, TRC101 3 g twice daily =6, TRC101 4.5 g twice daily =8), ≥6 mEq/L (pooled placebo =0, TRC101 1.5 g twice daily =3, TRC101 6 g once daily =5, TRC101 3 g twice daily =3, TRC101 4.5 g twice daily =4), and ≥7 mEq/L (pooled placebo =0, TRC101 1.5 g twice daily =1, TRC101 6 g once daily =1, TRC101 3 g twice daily =2, TRC101 4.5 g twice daily =2). David A. Bushinsky et al. CJASN 2018;13:26-35 ©2018 by American Society of Nephrology